Literature DB >> 33499192

Dopamine in Health and Disease: Much More Than a Neurotransmitter.

Rafael Franco1,2, Irene Reyes-Resina1, Gemma Navarro1,3.   

Abstract

Dopamine is derived from an amino acid, phenylalanine, which must be obtained through the diet. Dopamine, known primarily to be a neurotransmitter involved in almost any higher executive action, acts through five types of G-protein-coupled receptors. Dopamine has been studied extensively for its neuronal handling, synaptic actions, and in relation to Parkinson's disease. However, dopamine receptors can be found extra-synaptically and, in addition, they are not only expressed in neurons, but in many types of mammalian cells, inside and outside the central nervous system (CNS). Recent studies show a dopamine link between the gut and the CNS; the mechanisms are unknown, but they probably require cells to act as mediators and the involvement of the immune system. In fact, dopamine receptors are expressed in almost any cell of the immune system where dopamine regulates various processes, such as antigen presentation, T-cell activation, and inflammation. This likely immune cell-mediated linkage opens up a new perspective for the use of dopamine-related drugs, i.e., agonist-antagonist-allosteric modulators of dopamine receptors, in a variety of diseases.

Entities:  

Keywords:  G protein-coupled receptors; L-DOPA; Parkinson’s disease; T-cell activation; drug development; immune system; inflammation; intestinal flora; microbiota; receptor heteromers

Year:  2021        PMID: 33499192      PMCID: PMC7911410          DOI: 10.3390/biomedicines9020109

Source DB:  PubMed          Journal:  Biomedicines        ISSN: 2227-9059


  103 in total

1.  Inhibition of nigral dopamine neurons by systemic and local apomorphine: possible contribution of dendritic autoreceptors.

Authors:  H Akaoka; P Charléty; C F Saunier; M Buda; G Chouvet
Journal:  Neuroscience       Date:  1992-08       Impact factor: 3.590

Review 2.  The discovery of dopamine deficiency in the parkinsonian brain.

Authors:  O Hornykiewicz
Journal:  J Neural Transm Suppl       Date:  2006

Review 3.  Clinical utility of monoamine neurotransmitter metabolite analysis in cerebrospinal fluid.

Authors:  Keith Hyland
Journal:  Clin Chem       Date:  2008-02-29       Impact factor: 8.327

4.  Understanding the role of heteroreceptor complexes in the central nervous system.

Authors:  Kjell Fuxe; Dasiel Borroto-Escuela; Gilberto Fisone; Luigi F Agnati; Sergio Tanganelli
Journal:  Curr Protein Pept Sci       Date:  2014       Impact factor: 3.272

Review 5.  Changes in cerebral dopamine metabolism and receptors during one-year neuroleptic administration and subsequent withdrawal: relevance to brain biochemistry in schizophrenia.

Authors:  A Clow; P Jenner; A Theodorou; C D Marsden
Journal:  Adv Biochem Psychopharmacol       Date:  1980

6.  Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson's disease.

Authors:  Hugo González; Francisco Contreras; Carolina Prado; Daniela Elgueta; Dafne Franz; Sebastián Bernales; Rodrigo Pacheco
Journal:  J Immunol       Date:  2013-04-15       Impact factor: 5.422

7.  Building a new conceptual framework for receptor heteromers.

Authors:  Sergi Ferré; Ruben Baler; Michel Bouvier; Marc G Caron; Lakshmi A Devi; Thierry Durroux; Kjell Fuxe; Susan R George; Jonathan A Javitch; Martin J Lohse; Ken Mackie; Graeme Milligan; Kevin D G Pfleger; Jean-Philippe Pin; Nora D Volkow; Maria Waldhoer; Amina S Woods; Rafael Franco
Journal:  Nat Chem Biol       Date:  2009-03       Impact factor: 15.040

Review 8.  Volume transmission and receptor-receptor interactions in heteroreceptor complexes: understanding the role of new concepts for brain communication.

Authors:  Kjell Fuxe; Dasiel O Borroto-Escuela
Journal:  Neural Regen Res       Date:  2016-08       Impact factor: 5.135

Review 9.  Underlying Susceptibility to Eating Disorders and Drug Abuse: Genetic and Pharmacological Aspects of Dopamine D4 Receptors.

Authors:  Luca Botticelli; Emanuela Micioni Di Bonaventura; Fabio Del Bello; Gianfabio Giorgioni; Alessandro Piergentili; Adele Romano; Wilma Quaglia; Carlo Cifani; Maria Vittoria Micioni Di Bonaventura
Journal:  Nutrients       Date:  2020-07-30       Impact factor: 5.717

Review 10.  Mechanism of Action of Atypical Antipsychotic Drugs in Mood Disorders.

Authors:  Daniil Grinchii; Eliyahu Dremencov
Journal:  Int J Mol Sci       Date:  2020-12-15       Impact factor: 6.208

View more
  13 in total

Review 1.  Dopamine Receptors: Is It Possible to Become a Therapeutic Target for Depression?

Authors:  Fangyi Zhao; Ziqian Cheng; Jingjing Piao; Ranji Cui; Bingjin Li
Journal:  Front Pharmacol       Date:  2022-08-17       Impact factor: 5.988

2.  VEGF-A controls the expression of its regulator of angiogenic functions, dopamine D2 receptor, on endothelial cells.

Authors:  Chandrani Sarkar; Debanjan Chakroborty; Sandeep Goswami; Hao Fan; Xiaokui Mo; Sujit Basu
Journal:  J Cell Sci       Date:  2022-05-31       Impact factor: 5.235

3.  Dopamine Transporter Genetic Reduction Induces Morpho-Functional Changes in the Enteric Nervous System.

Authors:  Silvia Cerantola; Valentina Caputi; Gabriella Contarini; Maddalena Mereu; Antonella Bertazzo; Annalisa Bosi; Davide Banfi; Dante Mantini; Cristina Giaroni; Maria Cecilia Giron
Journal:  Biomedicines       Date:  2021-04-24

Review 4.  The Role of Glia in Addiction: Dopamine as a Modulator of Glial Responses in Addiction.

Authors:  Ariadna Jiménez-González; Claudia Gómez-Acevedo; Abraham Ochoa-Aguilar; Anahí Chavarría
Journal:  Cell Mol Neurobiol       Date:  2021-05-31       Impact factor: 4.231

5.  5-Hydroxytryptamine, Glutamate, and ATP: Much More Than Neurotransmitters.

Authors:  Rafael Franco; Rafael Rivas-Santisteban; Jaume Lillo; Jordi Camps; Gemma Navarro; Irene Reyes-Resina
Journal:  Front Cell Dev Biol       Date:  2021-04-15

6.  Gastrointestinal Dopamine in Inflammatory Bowel Diseases: A Systematic Review.

Authors:  Magdalena Kurnik-Łucka; Paweł Pasieka; Patrycja Łączak; Marcin Wojnarski; Michał Jurczyk; Krzysztof Gil
Journal:  Int J Mol Sci       Date:  2021-11-29       Impact factor: 5.923

7.  Improving Mood and Cognitive Symptoms in Huntington's Disease With Cariprazine Treatment.

Authors:  Maria Judit Molnar; Viktor Molnar; Mariann Fedor; Reka Csehi; Karoly Acsai; Beata Borsos; Zoltan Grosz
Journal:  Front Psychiatry       Date:  2022-02-10       Impact factor: 4.157

Review 8.  Chemical and Biological Molecules Involved in Differentiation, Maturation, and Survival of Dopaminergic Neurons in Health and Parkinson's Disease: Physiological Aspects and Clinical Implications.

Authors:  Giulia Gaggi; Andrea Di Credico; Pascal Izzicupo; Giovanni Iannetti; Angela Di Baldassarre; Barbara Ghinassi
Journal:  Biomedicines       Date:  2021-06-29

Review 9.  Roles of Transcription Factors in the Development and Reprogramming of the Dopaminergic Neurons.

Authors:  Lulu Tian; Murad Al-Nusaif; Xi Chen; Song Li; Weidong Le
Journal:  Int J Mol Sci       Date:  2022-01-13       Impact factor: 5.923

10.  Glutamate as a Stressoric Factor for the Ex Vivo Release of Catecholamines from the Rabbit Medial Prefrontal Cortex (mPFC).

Authors:  Bogdan Feliks Kania; Danuta Wrońska; Izabela Szpręgiel; Urszula Bracha
Journal:  Life (Basel)       Date:  2021-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.